Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) marked $6.09 per share on Monday, down from a previous closing price of $6.25. While Y-mAbs Therapeutics Inc. has underperformed by -2.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -63.77%, with highs and lows ranging from $20.48 to $2.70, whereas the simple moving average fell by -0.05% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On May 10, 2023, Wedbush Upgraded Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) to Outperform.
Analysis of Y-mAbs Therapeutics Inc. (YMAB)
Further, the quarter-over-quarter increase in sales is 93.30%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Y-mAbs Therapeutics Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -64.80% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.40, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 299.08K can be a very valuable indicator of volatility for YMAB stock. On a monthly basis, the volatility of the stock is set at 5.99%, whereas on a weekly basis, it is put at 6.14%, with a loss of -2.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.86, showing growth from the present price of $6.09, which can serve as yet another indication of whether YMAB is worth investing in or should be passed over.
How Do You Analyze Y-mAbs Therapeutics Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.30%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 65.80% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in YMAB shares?
The recent increase in stakes in YMAB appears to be a result of several institutional investors and hedge funds increasing their positions. HBM Partners AG’s position in YMAB has increased by 23.39% in the first quarter. The company now owns 3,813,853 shares of the stock, with a value of $25.9 million, following the purchase of 722,899 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in YMAB during the first quarter, upping its stake by 2.03%. During the last quarter, the company dropped down 44,061 additional shares for a total stake of worth $15.02 million, bringing number of shares owned by the company to 2,212,113.
At the end of the first quarter, D. E. Shaw & Co. LP increased its YMAB holdings by 68.77% and now holds 0.79 million YMAB shares valued at $5.37 million with the added 0.32 million shares during the period. YMAB shares are owned by institutional investors to the tune of 65.80% at present.
